Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Consumer Health True To Form Pending Move To JV With GSK

Executive Summary

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

You may also be interested in...



Q4 Consumer Health Earnings Preview: GSK, Bayer, RB, And Sanofi

GSK is looking to close out 2018 strongly as it prepares to launch its Consumer Health JV with Pfizer, while Bayer will be glad to see the back of a tough year. Elsewhere, RB is preparing for life after Rakesh Kapoor and Sanofi is ramping up its push into digital health.

GSK And Pfizer Start Consumer JV For Different Reasons, Aim For Similar Goals

Big pharmas' agreement could put consumer health where Pfizer wants, entirely in its rear-view mirror, and points GSK toward what it wants, more research and development funding freed up for the pharmaceutical ingredient operations that are its chief revenue drivers. All-equity deal, giving GSK 68% control and expected to close in 2019 second half, also likely will boost investors' confidence in the firms as both have been dogged by pressure to sell, spin-off or otherwise divest their consumer businesses.

Pfizer elevates Bourla as Read steps down

Pfizer’s chief executive officer Ian Read is to step down after eight years at the helm of the US pharma giant and take on the role of executive chairman. On 1 January 2019, he will be succeeded by chief operating officer Albert Bourla, who won the “unanimous support” of Pfizer’s board.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel